The binding of therapeutic compounds to plasma or serum proteins is an important factor to consider when assessing the Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) profile of a drug. Seattle Genova offers a well-established SPR assay for ranking drugs according to their ability to interact with the most abundant plasma proteins, limiting their availability and pharmacological potency.
20 Most Abundant Plasma Proteins
Complement C1 q
The use of Biacore systems for drug-target and drug-ADME target studies during both hit-to-lead and lead optimization phases of drug development can provide important insights on how plasma protein binding may impact drug dose and/or drug efficacy.
With state-of-the-art equipment and scientific expertise in drug-serum protein binding test, Seattle Genova is focused on providing cost-effective, high-quality, reproducible data and flexible solutions with fast turnaround times.
Thank you for your interest in our Serum Protein Binding (ADME) services. Please complete the form below and we will contact you shortly.
Fields indicated by an * are required.